Global Benign Prostatic Hyperplasia (BPH) Treatment Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Price

Description:

Scope of the Report:
The global Benign Prostatic Hyperplasia (BPH) Treatment market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Benign Prostatic Hyperplasia (BPH) Treatment.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Benign Prostatic Hyperplasia (BPH) Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Benign Prostatic Hyperplasia (BPH) Treatment market by product type and applications/end industries.
Market Segment by Companies, this report covers
Astellas Pharma
Eli Lilly
GlaxoSmithKline
Sanofi
Novartis
Teva
Boston Scientific
NxThera, Inc.(Rezum)
NeoTract, Inc.(UroLift)
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Drugs
Invasive Procedures
Device
Market Segment by Applications, can be divided into
Hospitals
Clinics
Other

Table of Contents

1 Benign Prostatic Hyperplasia (BPH) Treatment Market Overview

1.1 Product Overview and Scope of Benign Prostatic Hyperplasia (BPH) Treatment
1.2 Classification of Benign Prostatic Hyperplasia (BPH) Treatment by Types
  1.2.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Comparison by Types (2019-2024)
  1.2.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Types in 2018
  1.2.3 Drugs
  1.2.4 Invasive Procedures
  1.2.5 Device
1.3 Global Benign Prostatic Hyperplasia (BPH) Treatment Market by Application
  1.3.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Market Share Comparison by Applications (2014-2024)
  1.3.2 Hospitals
  1.3.3 Clinics
  1.3.4 Other
1.4 Global Benign Prostatic Hyperplasia (BPH) Treatment Market by Regions
  1.4.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size (Million USD) Comparison by Regions (2014-2024)
  1.4.2 North America (USA, Canada and Mexico) Benign Prostatic Hyperplasia (BPH) Treatment Status and Prospect (2014-2024)
  1.4.3 Europe (Germany, France, UK, Russia and Italy) Benign Prostatic Hyperplasia (BPH) Treatment Status and Prospect (2014-2024)
  1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Benign Prostatic Hyperplasia (BPH) Treatment Status and Prospect (2014-2024)
1.4.4 South America (Brazil, Argentina, Colombia) Benign Prostatic Hyperplasia (BPH) Treatment Status and Prospect (2014-2024)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Benign Prostatic Hyperplasia (BPH) Treatment Status and Prospect (2014-2024)

2 Manufacturers Profiles
2.1 Astellas Pharma
   2.1.1 Business Overview
   2.1.2 Benign Prostatic Hyperplasia (BPH) Treatment Type and Applications
      2.1.2.1 Product A
      2.1.2.2 Product B
   2.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2018)
2.2 Eli Lilly
   2.2.1 Business Overview
   2.2.2 Benign Prostatic Hyperplasia (BPH) Treatment Type and Applications
      2.2.2.1 Product A
      2.2.2.2 Product B
   2.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2018)
2.3 GlaxoSmithKline
   2.3.1 Business Overview
   2.3.2 Benign Prostatic Hyperplasia (BPH) Treatment Type and Applications
      2.3.2.1 Product A
      2.3.2.2 Product B
   2.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2018)
2.4 Sanofi
   2.4.1 Business Overview
   2.4.2 Benign Prostatic Hyperplasia (BPH) Treatment Type and Applications
      2.4.2.1 Product A
      2.4.2.2 Product B
   2.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2018)
2.5 Novartis
   2.5.1 Business Overview
   2.5.2 Benign Prostatic Hyperplasia (BPH) Treatment Type and Applications
      2.5.2.1 Product A
      2.5.2.2 Product B
   2.5.3 Novartis Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2018)
2.6 Teva
   2.6.1 Business Overview
   2.6.2 Benign Prostatic Hyperplasia (BPH) Treatment Type and Applications
      2.6.2.1 Product A
      2.6.2.2 Product B
   2.6.3 Teva Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2018)
2.7 Boston Scientific
   2.7.1 Business Overview
   2.7.2 Benign Prostatic Hyperplasia (BPH) Treatment Type and Applications
      2.7.2.1 Product A
      2.7.2.2 Product B
   2.7.3 Boston Scientific Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2018)
2.8 NxThera, Inc.(Rezum)
   2.8.1 Business Overview
   2.8.2 Benign Prostatic Hyperplasia (BPH) Treatment Type and Applications
      2.8.2.1 Product A
      2.8.2.2 Product B
   2.8.3 NxThera, Inc.(Rezum) Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2018)
2.9 NeoTract, Inc.(UroLift)
   2.9.1 Business Overview
   2.9.2 Benign Prostatic Hyperplasia (BPH) Treatment Type and Applications
      2.9.2.1 Product A
      2.9.2.2 Product B
   2.9.3 NeoTract, Inc.(UroLift) Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2017-2018)

3 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Competition, by Players
3.2 Market Concentration Rate
   3.2.1 Top 5 Benign Prostatic Hyperplasia (BPH) Treatment Players Market Share
   3.2.2 Top 10 Benign Prostatic Hyperplasia (BPH) Treatment Players Market Share
3.3 Market Competition Trend

4 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Regions
4.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Market Share by Regions
4.2 North America Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
4.3 Europe Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
4.4 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
4.5 South America Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
4.6 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)

5 North America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Countries
- 5.2 USA Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
- 5.3 Canada Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
- 5.4 Mexico Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)

6 Europe Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Countries
- 6.1 Europe Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Countries (2014-2019)
- 6.2 Germany Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
- 6.3 UK Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
- 6.4 France Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
- 6.5 Russia Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
- 6.6 Italy Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Countries
- 7.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Countries (2014-2019)
- 7.2 China Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
- 7.3 Japan Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
- 7.4 Korea Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
- 7.5 India Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
- 7.6 Southeast Asia Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)

8 South America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Countries
- 8.1 South America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Countries (2014-2019)
- 8.2 Brazil Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
- 8.3 Argentina Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
- 8.4 Colombia Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Benign Prostatic Hyperplasia (BPH) Treatment by Countries
- 9.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Countries (2014-2019)
- 9.3 UAE Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
- 9.4 Egypt Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
- 9.5 Nigeria Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)
- 9.6 South Africa Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2014-2019)

10 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Segment by Type
- 10.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Market Share by Type (2014-2019)
- 10.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Forecast by Type (2019-2024)
- 10.3 Drugs Revenue Growth Rate (2014-2024)
- 10.4 Invasive Procedures Revenue Growth Rate (2014-2024)
- 10.5 Device Revenue Growth Rate (2014-2024)

11 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Segment by Application
- 11.3 Hospitals Revenue Growth (2014-2019)
- 11.4 Clinics Revenue Growth (2014-2019)
- 11.5 Other Revenue Growth (2014-2019)

12 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Forecast (2019-2024)
- 12.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Forecast (2019-2024)
- 12.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Forecast by Regions (2019-2024)
- 12.3 North America Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Forecast (2019-2024)
- 12.4 Europe Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Forecast (2019-2024)
- 12.5 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Forecast (2019-2024)
- 12.6 South America Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Forecast (2019-2024)
- 12.7 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix
- 14.1 Methodology